Psoriatic Arthritis: Competitive Landscape to 2026

Psoriatic arthritis is a chronic immune-mediated arthritis that typically affects the large joints, including those of the lower extremities, the distal joints of the fingers and toes, the back, and sacroiliac joints of the pelvis. Up to 30% of patients with psoriasis, an immune-mediated skin disease, develop psoriatic arthritis. In approximately 85% of psoriatic arthritis patients, skin lesions of psoriasis manifest prior to the development of psoriatic arthritis, typically by 5–10 years. Psoriatic arthritis most commonly develops between the ages of 30–50 years and affects men and women equally. While no definitive cause of psoriatic arthritis has been established, research suggests a multifactorial pathogenesis involving genetics, the environment, and infectious agents.

This report provides an assessment of the pipeline, clinical, and commercial landscape of psoriatic arthritis. Overall, GlobalData expects new drug approvals to drive market growth over the next decade (2016–2026).


GlobalData’s Psoriatic Arthritis: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

• Commercial Assessment—leading marketed products, current and future players

• Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global psoriatic arthritis market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global psoriatic arthritis market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned



Bristol-Myers Squibb


Eli Lilly

Johnson & Johnson




Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview & Epidemiology Overview

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Early-Stage Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in Psoriatic Arthritis

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan

7.5 Australia

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer


Discounts available for multiple report purchases.
+44 (0) 161 359 5813

Join our mailing list

Saved reports